Timothy Edward Hodge

Works (1)

Updated: July 5th, 2023 15:41

2014 article

Case-control study of the effects of pimobendan on survival time in cats with hypertrophic cardiomyopathy and congestive heart failure

Reina-Doreste, Y., Stern, J. A., Keene, B. W., Tou, S. P., Atkins, C. E., DeFrancesco, T. C., … Meurs, K. M. (2014, August 22). Journal of the American Veterinary Medical Association, Vol. 245, pp. 534–539.

By: Y. Reina-Doreste n, J. Stern* , B. Keene n, S. Tou n , C. Atkins n, T. DeFrancesco n , M. Ames n, T. Hodge n, K. Meurs n 

MeSH headings : Animals; Cardiomyopathy, Hypertrophic / drug therapy; Cardiomyopathy, Hypertrophic / mortality; Cardiomyopathy, Hypertrophic / veterinary; Cardiotonic Agents / therapeutic use; Case-Control Studies; Cat Diseases / drug therapy; Cat Diseases / mortality; Cats; Female; Heart Failure / drug therapy; Heart Failure / mortality; Heart Failure / veterinary; Male; Pyridazines / therapeutic use; Retrospective Studies
topics (OpenAlex): Cardiovascular Conditions and Treatments; Congenital Heart Disease Studies; Cardiac Arrhythmias and Treatments
TL;DR: The addition of pimobendan to traditional treatment for CHF may provide a substantial clinical benefit in survival time for HCM-affected cats with CHF and possibly HOCM- affected cats withCHF. (via Semantic Scholar)
UN Sustainable Development Goals Color Wheel
UN Sustainable Development Goal Categories
3. Good Health and Well-being (Web of Science; OpenAlex)
Sources: Web Of Science, NC State University Libraries, ORCID
Added: August 6, 2018

Citation Index includes data from a number of different sources. If you have questions about the sources of data in the Citation Index or need a set of data which is free to re-distribute, please contact us.

Certain data included herein are derived from the Web of Science© and InCites© (2026) of Clarivate Analytics. All rights reserved. You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.